Predicting pregnancy complications with high-plex proteomics
A SomaLogic boutique webinar
Predicting pregnancy complications with high-plex proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth. In this webinar, Dr. Lucy Bartho delves into the transformative role of SomaLogic’s SomaScan® assay in their biomarker discovery endeavors. She will also elaborate on how this technology has facilitated the development of clinical tools for the early identification of preeclampsia and fetal growth restriction.
Lucy Bartho, PhD
Dr. Lucy Bartho is a postdoctoral fellow from the Translational Obstetrics Group at the University of Melbourne, co-led by Professor Stephen Tong and Professor Tu’uhevaha Kaitu’u-Lino. The team of 10-15 scientists and clinician-scientists is dedicated to developing diagnostics and therapeutics aimed at enhancing the care of pregnant women and their fetuses. The research arising from the team focuses on identifying novel biomarkers for predicting pregnancy complications, developing treatments for ectopic pregnancy and preeclampsia, and elucidating the pathogenesis of these conditions.
Predicting pregnancy complications with high-plex proteomics
A presentation by Lucy Bartho, PhD
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.